Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verve Therapeutics Inc (NQ: VERV )

4.500 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verve Therapeutics Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
From Verve Therapeutics
Via GlobeNewswire
2 Incredible Growth Stocks Near 52-Week Lows to Buy Now
These two high-tech bio companies may be too cheap to ignore right now. 
Via The Motley Fool
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi... 
Via Benzinga
1 Cathie Wood Stock That Could Go Parabolic Soon
This next-gen biotech stock is barreling toward a major catalyst. 
Via The Motley Fool
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023
Company to hold investor event in conjunction with data presentation on November 12, 2023 
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
From Verve Therapeutics
Via GlobeNewswire
Expert Ratings for Verve Therapeutics
Via Benzinga
Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
From Verve Therapeutics
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 99 stocks hit new 52-week lows. 
Via Benzinga
Disinflation Talk Grows, Rate Hike Bets Plummet: Top 5 ETFs Rallying On CPI Miss
The disinflationary trend continued in July, even though the annual CPI inflation rate saw a slight increase from 3% to 3.2% last month, breaking a streak of 12 consecutive months of decline. 
Via Benzinga
Topics ETFs Economy
Exposures Interest Rates
Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference
From Verve Therapeutics
Via GlobeNewswire
Jim Cramer Says It's Time To Buy This Financial Services Stock Down 32% YTD
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Illumina, Inc. (NASDAQ: ILMN) is not even as good as Danaher Corporation (NYSE: DHR). 
Via Benzinga
Cathie Wood Is Buying This Biotech, but Here's Why I'm Not
The risks are too high, and it'll take a while for them to be addressed. 
Via The Motley Fool
Cathie Wood Buys More Meta Shares As Mark Zuckerberg Goes All-In On Twitter Rivalry
Via Benzinga
Cathie Wood Continues To Sell Tesla Shares Amid Q2 Deliveries-Induced Strength: Here's How Much Shares Ark Offloaded Monday
Via Benzinga
Verve Therapeutics Gains 20.74% In June as Ark Funds Invest
Verve Therapeutics' efforts to eliminate cardiovascular disease through gene-editing treatments have momentum, as the stock gets a 20.74% boost in June. 
Via MarketBeat
5 Short Squeeze Stocks In Play Thursday: Nikola, Verve, Carvana, More
Via Benzinga
Crude Oil Rises Sharply; Jabil Posts Upbeat Q3 Results
U.S. stocks traded higher toward the end of trading, with Dow Jones gaining around 450 points on Thursday. The Dow traded up 1.32% to 34,429.39 while the NASDAQ rose 1.27% to 13,799.28. The S&P 500,... 
Via Benzinga
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million
Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A. 
Via Investor's Business Daily
Domino's Pizza, Patterson-UTI Energy, JinkoSolar And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 180 points on Thursday. Here are some big stocks recording gains in today’s session. Nikola Corporation (NASDAQ: NKLA) jumped 19.9% to... 
Via Benzinga
Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Why These 3 Nasdaq Stocks Were Glowing Green This Week
These three biopharmaceutical stocks rocketed higher this week. 
Via The Motley Fool
Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference
From Verve Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
Via Benzinga
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.